A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Latest Information Update: 30 Aug 2024
At a glance
- Drugs Cemsidomide (Primary) ; Dexamethasone (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors C4 Therapeutics
- 28 Aug 2024 Planned number of patients changed from 164 to 224.
- 30 Apr 2024 Planned End Date changed from 7 Dec 2024 to 7 Dec 2025.
- 30 Apr 2024 Planned primary completion date changed from 7 Sep 2024 to 7 Sep 2025.